CIZZLE BIOTECHNOLOGY LIMITED

• ⚠

  Material uncertainty over going concern

  After taking into account these conditions, it indicates that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. These financial statements do not include any adjustments that would result from the going concern basis of preparation being inappropriate. These scenarios show that the Group is reliant upon the timely receipt of the balance ($US1.81m) of Guaranteed Minimum Royalty Payments (GMP) from Cizzle Bio Inc ("BIO")...However, there remains uncertainty if BIO will be able to make these payments as it is dependent on raising further funds. Should these royalty payments be delayed or not materialise, then the company may be required to raise additional funding to continue to meet its obligations.

1. CIZZLE BIOTECHNOLOGY LIMITED 2005-04-12 → present
2. M&R 971 LIMITED 2004-10-04 → 2005-04-12

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“After taking into account these conditions, it indicates that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. These financial statements do not include any adjustments that would result from the going concern basis of preparation being inappropriate. These scenarios show that the Group is reliant upon the timely receipt of the balance ($US1.81m) of Guaranteed Minimum Royalty Payments (GMP) from Cizzle Bio Inc ("BIO")...However, there remains uncertainty if BIO will be able to make these payments as it is dependent on raising further funds. Should these royalty payments be delayed or not materialise, then the company may be required to raise additional funding to continue to meet its obligations.”

Significant events

• “On 18 August 2025, the Group provided an update on the progress to launch the commercial test in the USA confirming that BIO had initiated a US national strategy for accreditation and market launch across multiple sites.”
• “On 29 September it was announced that to achieve this, BIO would be partnering with Omni Health Diagnostics ("Omni") a CLIA-certified diagnostic laboratory.”
• “On 5 November 2025, that it had entered into a Letter of Intent ("LOI") with a leading medical diagnostic services provider acting in partnership with the NHS.”
• “On 23 February 2026 the Group announced that the Parent Company and Cizzle Bio have agreed to a minimum of US$3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031.”
• “On 2 April 2026, the Group announced that it has entered into a new facility (the "Facility") to provide the Parent Company with up to £250,000 through the potential issue of further unsecured convertible loan notes.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -67.5%

  £342,000 → £111,000

• Net assets

  -25.6%

  -£821,000 → -£1,031,000

• Employees

  —

  Not reported

• Operating profit

  -68.8%

  -£160,000 → -£270,000

• Profit before tax

  -68.8%

  -£160,000 → -£270,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers